Ceftazidime

Chemical formula: C₂₂H₂₂N₆O₇S₂  Molecular mass: 546.576 g/mol  PubChem compound: 5481173

Therapeutic indications

Ceftazidime is indicated for:

Broncho-pulmonary infections in cystic fibrosis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Bronchial sepsis
Pulmonary infection
and additionally Cystic fibrosis
and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Febrile neutropenia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Febrile neutropenia and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nosocomial pneumonia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Nosocomial pneumonia and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacterial meningitis and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bone and joint infections, complicated skin and soft tissue infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Infection of bone
Infectious disorder of joint
Soft tissue infection
and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated intra-abdominal infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Infectious disease of abdomen and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Peritonitis associated with dialysis in patients on CAPD

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Peritoneal dialysis-associated peritonitis and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infectious disease and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Peri-operative prophylaxis for transuretheral resection of prostate (TURP)

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Preventive procedure and additionally Transurethral prostatectomy

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic purulent otitis media, malignant otitis externa

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Chronic purulent otitis media
Malignant otitis externa
and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Urinary tract infectious disease and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic purulent otitis media, malignant otitis externa

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Chronic purulent otitis media
Malignant otitis externa
and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Febrile neutropenia

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Febrile neutropenia and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Broncho-pulmonary infections in cystic fibrosis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Bronchial sepsis
Pulmonary infection
and additionally Cystic fibrosis
and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial meningitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Bacterial meningitis and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bone and joint infections, complicated skin and soft tissue infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Infection of bone
Infectious disorder of joint
Soft tissue infection
and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated intra-abdominal infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Infectious disease of abdomen and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Peritonitis associated with dialysis in patients on CAPD

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Peritoneal dialysis-associated peritonitis and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Nosocomial pneumonia

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Nosocomial pneumonia and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial infections

Population group: only newborns (0 - 40 days old)

Infectious disease and additionally at least one of
Ceftazidime susceptible species
Ceftazidime susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ceftazidime is contraindicated in the following cases:

Hypersensitivity to cephalosporins, history of severe hypersensitivity to penicillins, monobactams or carbapenems

at least one of
Cephalosporin allergy
Allergy to penicillin
Monobactam allergy
Carbapenem allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: CEFTAZIDIME Powder for solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈